{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T12:08:30Z","timestamp":1785154110759,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["82070130"],"award-info":[{"award-number":["82070130"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["82070130"],"award-info":[{"award-number":["82070130"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["82070130"],"award-info":[{"award-number":["82070130"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["82070130"],"award-info":[{"award-number":["82070130"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00277-025-06296-z","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T11:48:45Z","timestamp":1744026525000},"page":"2869-2879","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Incidence and risk factors of severe infections in diffuse large B-cell lymphoma patients undergoing immunochemotherapy"],"prefix":"10.1007","volume":"104","author":[{"given":"Haiqiu","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"6296_CR1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36:1720\u20131748","journal-title":"Leukemia"},{"key":"6296_CR2","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR et al (2022) The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood 140:1229\u20131253","journal-title":"Blood"},{"key":"6296_CR3","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G (2021) Diffuse large B-Cell lymphoma. N Engl J Med 384:842\u2013858","journal-title":"N Engl J Med"},{"key":"6296_CR4","doi-asserted-by":"crossref","first-page":"102443","DOI":"10.1016\/j.ctrv.2022.102443","volume":"110","author":"S Poletto","year":"2022","unstructured":"Poletto S, Novo M, Paruzzo L et al (2022) Treatment strategies for patients with diffuse large B-cell lymphoma. Cancer Treat Rev 110:102443","journal-title":"Cancer Treat Rev"},{"key":"6296_CR5","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E et al (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the groupe d\u2019etudes des lymphomes de L\u2019Adulte. Blood 116:2040\u20132045","journal-title":"Blood"},{"key":"6296_CR6","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Trumper L, Osterborg A et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (MInT) group. Lancet Oncol 7:379\u2013391","journal-title":"Lancet Oncol"},{"key":"6296_CR7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M et al (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20\u2009+\u2009B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9:105\u2013116","journal-title":"Lancet Oncol"},{"key":"6296_CR8","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, Van Hoof A, Sebban C et al (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the groupe d\u2019etude des lymphomes de L\u2019Adulte. J Clin Oncol 23:4117\u20134126","journal-title":"J Clin Oncol"},{"key":"6296_CR9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH et al (2022) Polatuzumab Vedotin in previously untreated diffuse large B-Cell lymphoma. N Engl J Med 386:351\u2013363","journal-title":"N Engl J Med"},{"key":"6296_CR10","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1002\/cncr.30739","volume":"123","author":"N Howlader","year":"2017","unstructured":"Howlader N, Mariotto AB, Besson C et al (2017) Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era. Cancer 123:3326\u20133334","journal-title":"Cancer"},{"key":"6296_CR11","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1038\/s41598-017-04495-x","volume":"7","author":"C Dendle","year":"2017","unstructured":"Dendle C, Gilbertson M, Spelman T et al (2017) Infection is an independent predictor of death in diffuse large B cell lymphoma. Sci Rep 7:4395","journal-title":"Sci Rep"},{"key":"6296_CR12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clml.2012.06.004","volume":"12","author":"P Lugtenburg","year":"2012","unstructured":"Lugtenburg P, Silvestre AS, Rossi FG et al (2012) Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens. Clin Lymphoma Myeloma Leuk 12:297\u2013305","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6296_CR13","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1080\/10428194.2016.1265111","volume":"58","author":"VA Morrison","year":"2017","unstructured":"Morrison VA, Weller EA, Habermann TM et al (2017) Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the intergroup experience (CALGB 9793; ECOG-SWOG 4494). Leuk Lymphoma 58:1814\u20131822","journal-title":"Leuk Lymphoma"},{"key":"6296_CR14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/onco.13610","volume":"26","author":"M Di","year":"2021","unstructured":"Di M, Huntington SF, Olszewski AJ (2021) Challenges and opportunities in the management of diffuse large B-Cell lymphoma in older patients. Oncologist 26:120\u2013132","journal-title":"Oncologist"},{"key":"6296_CR15","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/bloodadvances.2021004286","volume":"5","author":"TA Eyre","year":"2021","unstructured":"Eyre TA, Wilson W, Kirkwood AA et al (2021) Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP. Blood Adv 5:2229\u20132236","journal-title":"Blood Adv"},{"key":"6296_CR16","doi-asserted-by":"crossref","first-page":"e200211","DOI":"10.1212\/NXI.0000000000200211","volume":"11","author":"A Langer-Gould","year":"2024","unstructured":"Langer-Gould A, Li BH, Smith JB, Xu S (2024) Multiple sclerosis, rituximab, hypogammaglobulinemia, and risk of infections. Neurol Neuroimmunol Neuroinflamm 11:e200211","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"6296_CR17","doi-asserted-by":"crossref","unstructured":"Davis JS, Ferreira D, Paige E et al (2020) Infectious complications of biological and small molecule targeted Immunomodulatory therapies. Clin Microbiol Rev 33","DOI":"10.1128\/CMR.00035-19"},{"key":"6296_CR18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hon.947","volume":"29","author":"T Kurokawa","year":"2011","unstructured":"Kurokawa T, Hase M, Tokuman N, Yoshida T (2011) Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab. Hematol Oncol 29:5\u20139","journal-title":"Hematol Oncol"},{"key":"6296_CR19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.4143\/crt.2014.034","volume":"47","author":"S Park","year":"2015","unstructured":"Park S, Kang CI, Chung DR et al (2015) Clinical significance of Non-neutropenic fever in the management of diffuse large B-Cell lymphoma patients treated with Rituximab-CHOP: comparison with febrile neutropenia and risk factor analysis. Cancer Res Treat 47:448\u2013457","journal-title":"Cancer Res Treat"},{"key":"6296_CR20","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ajh.24499","volume":"91","author":"JN Barreto","year":"2016","unstructured":"Barreto JN, Ice LL, Thompson CA et al (2016) Low incidence of Pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy. Am J Hematol 91:1113\u20131117","journal-title":"Am J Hematol"},{"key":"6296_CR21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000334113","volume":"127","author":"E Hardak","year":"2012","unstructured":"Hardak E, Oren I, Dann EJ et al (2012) The increased risk for Pneumocystis pneumonia in patients receiving rituximab-CHOP-14 can be prevented by the administration of Trimethoprim\/sulfamethoxazole: a single-center experience. Acta Haematol 127:110\u2013114","journal-title":"Acta Haematol"},{"key":"6296_CR22","doi-asserted-by":"crossref","first-page":"e0122171","DOI":"10.1371\/journal.pone.0122171","volume":"10","author":"X Jiang","year":"2015","unstructured":"Jiang X, Mei X, Feng D, Wang X (2015) Prophylaxis and treatment of Pneumocystis Jiroveci pneumonia in lymphoma patients subjected to Rituximab-Contained therapy: A systemic review and Meta-Analysis. PLoS ONE 10:e0122171","journal-title":"PLoS ONE"},{"key":"6296_CR23","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s11899-013-0171-4","volume":"8","author":"MK Keng","year":"2013","unstructured":"Keng MK, Sekeres MA (2013) Febrile neutropenia in hematologic malignancies. Curr Hematol Malig Rep 8:370\u2013378","journal-title":"Curr Hematol Malig Rep"},{"key":"6296_CR24","doi-asserted-by":"crossref","first-page":"100738","DOI":"10.1016\/j.blre.2020.100738","volume":"46","author":"A Ohmoto","year":"2021","unstructured":"Ohmoto A, Fuji S (2021) Infection profiles of different chemotherapy regimens and the clinical feasibility of antimicrobial prophylaxis in patients with DLBCL. Blood Rev 46:100738","journal-title":"Blood Rev"},{"key":"6296_CR25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11926-021-01037-3","volume":"23","author":"CD Varley","year":"2021","unstructured":"Varley CD, Winthrop KL (2021) Long-Term safety of rituximab (Risks of viral and opportunistic Infections). Curr Rheumatol Rep 23:74","journal-title":"Curr Rheumatol Rep"},{"key":"6296_CR26","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","volume":"14","author":"L Pagano","year":"2021","unstructured":"Pagano L, Salmanton-Garcia J, Marchesi F et al (2021) COVID-19 infection in adult patients with hematological malignancies: a European hematology association survey (EPICOVIDEHA). J Hematol Oncol 14:168","journal-title":"J Hematol Oncol"},{"key":"6296_CR27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3904\/kjim.2010.25.1.86","volume":"25","author":"KH Lim","year":"2010","unstructured":"Lim KH, Yoon HI, Kang YA et al (2010) Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab. Korean J Intern Med 25:86\u201392","journal-title":"Korean J Intern Med"},{"key":"6296_CR28","first-page":"1587","volume":"71","author":"A Khan","year":"2012","unstructured":"Khan A, Scott DL, Batley M (2012) Smoking, rheumatoid factor status and responses to rituximab. Ann Rheum Dis 71:1587\u20131588","journal-title":"Ann Rheum Dis"},{"key":"6296_CR29","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","volume":"111","author":"K Ekstrom Smedby","year":"2008","unstructured":"Ekstrom Smedby K, Vajdic CM, Falster M et al (2008) Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the interlymph consortium. Blood 111:4029\u20134038","journal-title":"Blood"},{"key":"6296_CR30","doi-asserted-by":"crossref","unstructured":"Bracci PM, Benavente Y, Turner JJ et al (2014) Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014:52\u201365","DOI":"10.1093\/jncimonographs\/lgu011"},{"key":"6296_CR31","doi-asserted-by":"crossref","unstructured":"Wang SS, Flowers CR, Kadin ME et al (2014) Medical history, lifestyle, family history, and occupational risk factors for peripheral T-cell lymphomas: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014:66\u201375","DOI":"10.1093\/jncimonographs\/lgu012"},{"key":"6296_CR32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/jncimonographs\/lgu003","volume":"2014","author":"SM Mbulaiteye","year":"2014","unstructured":"Mbulaiteye SM, Morton LM, Sampson JN et al (2014) Medical history, lifestyle, family history, and occupational risk factors for sporadic Burkitt lymphoma\/leukemia: the interlymph Non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr 2014:106\u2013114","journal-title":"J Natl Cancer Inst Monogr"},{"key":"6296_CR33","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.canep.2019.02.014","volume":"59","author":"E Kane","year":"2019","unstructured":"Kane E, Painter D, Smith A et al (2019) The impact of rheumatological disorders on lymphomas and myeloma: a report on risk and survival from the UK\u2019s population-based haematological malignancy research network. Cancer Epidemiol 59:236\u2013243","journal-title":"Cancer Epidemiol"},{"key":"6296_CR34","doi-asserted-by":"crossref","unstructured":"Frost E, Hofmann JN, Huang WY et al (2023) Antinuclear antibodies are associated with an increased risk of diffuse large B-Cell lymphoma. Cancers (Basel) 15","DOI":"10.3390\/cancers15215231"},{"key":"6296_CR35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/j.seminhematol.2023.11.004","volume":"60","author":"SS Wang","year":"2023","unstructured":"Wang SS (2023) Epidemiology and etiology of diffuse large B-cell lymphoma. Semin Hematol 60:255\u2013266","journal-title":"Semin Hematol"},{"key":"6296_CR36","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00520-011-1306-6","volume":"20","author":"R Pettengell","year":"2012","unstructured":"Pettengell R, Johnsen HE, Lugtenburg PJ et al (2012) Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Support Care Cancer 20:647\u2013652","journal-title":"Support Care Cancer"},{"issue":"Suppl 5","key":"6296_CR37","doi-asserted-by":"crossref","first-page":"v248","DOI":"10.1093\/annonc\/mdq195","volume":"21","author":"J Crawford","year":"2010","unstructured":"Crawford J, Caserta C, Roila F, Group EGW (2010) Hematopoietic growth factors: ESMO clinical practice guidelines for the applications. Ann Oncol 21(Suppl 5):v248\u2013251","journal-title":"Ann Oncol"},{"key":"6296_CR38","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/11586040-000000000-00000","volume":"50","author":"BB Yang","year":"2011","unstructured":"Yang BB, Kido A (2011) Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet 50:295\u2013306","journal-title":"Clin Pharmacokinet"},{"key":"6296_CR39","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/1471-2407-11-404","volume":"11","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S et al (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:404","journal-title":"BMC Cancer"},{"key":"6296_CR40","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00520-014-2457-z","volume":"23","author":"AM Pfeil","year":"2015","unstructured":"Pfeil AM, Allcott K, Pettengell R et al (2015) Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Support Care Cancer 23:525\u2013545","journal-title":"Support Care Cancer"},{"key":"6296_CR41","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/bjh.19273","volume":"204","author":"CP Fox","year":"2024","unstructured":"Fox CP, Chaganti S, McIlroy G et al (2024) The management of newly diagnosed large B-cell lymphoma: A British society for haematology guideline. Br J Haematol 204:1178\u20131192","journal-title":"Br J Haematol"},{"key":"6296_CR42","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1182\/blood-2010-07-259333","volume":"116","author":"M Pfreundschuh","year":"2010","unstructured":"Pfreundschuh M (2010) How I treat elderly patients with diffuse large B-cell lymphoma. Blood 116:5103\u20135110","journal-title":"Blood"},{"key":"6296_CR43","first-page":"2566","volume":"141","author":"PJ Lugtenburg","year":"2023","unstructured":"Lugtenburg PJ, Mutsaers P (2023) How I treat older patients with DLBCL in the frontline setting. Blood 141:2566\u20132575","journal-title":"Blood"},{"key":"6296_CR44","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jgo.2015.01.003","volume":"6","author":"KR Carson","year":"2015","unstructured":"Carson KR, Riedell P, Lynch R et al (2015) Comparative effectiveness of anthracycline-containing chemotherapy in united States veterans age 80 and older with diffuse large B-cell lymphoma. J Geriatr Oncol 6:211\u2013218","journal-title":"J Geriatr Oncol"},{"key":"6296_CR45","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00277-020-04345-3","volume":"100","author":"F Zettl","year":"2021","unstructured":"Zettl F, Ziepert M, Altmann B et al (2021) Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma-data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin\u2019s lymphoma study Group). Ann Hematol 100:1031\u20131038","journal-title":"Ann Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06296-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06296-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06296-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T06:38:02Z","timestamp":1749105482000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06296-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["6296"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06296-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University (2024-597-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The patient\u2019s consent was waived for retrospective study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}